Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07423299
PHASE1
A First-in-Human Single and Multiple Ascending Dose Study of MT-251
Sponsor: Mirador Therapeutics, Inc.
View on ClinicalTrials.gov
Summary
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Doses of MT-251 in Healthy Participants
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Doses of MT-251 in Healthy Participants
Key Details
Gender
All
Age Range
19 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2026-01-23
Completion Date
2027-03-08
Last Updated
2026-02-25
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
MT-251
MT-251
Locations (1)
Mirador Clinical Department
San Diego, California, United States